Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World rucaparib data: a closer look at ovarian cancer treatment

NCT ID NCT04539327

Knowledge-focused Sponsor: Grupo Español de Investigación en Cáncer de Ovario Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviewed medical records of 51 women with ovarian, fallopian tube, or peritoneal cancer who received the drug rucaparib in real-world clinics, not just in strict trials. Researchers looked at patient history, side effects, dosing, and how long the drug kept cancer from growing. The goal was to see if results from earlier clinical trials hold up in everyday practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

51 people

The number who actually took part.

Started

Jul 2020

Finished

Jul 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult (18 years or more) women diagnosed with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent must be signed by all patients participating in the study who can be interviewed in the hospital (accessible, alive patients). Informed consent may not be required from unaccessible patients (dead, lost, etc.) according to ethics committee permissions and applicable law for retrospective studies in Spain. 2. Histological diagnosis of high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer treated in the context of rucaparib access program (RAP) in Spain. 3. Adult women (18 years or more at the time of diagnosis). Exclusion Criteria: 1\. Patients without medical record available (lost, empty or unretrievable clinical information).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epithelial ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial fallopian tube cancer fallopian tube neoplasm ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer

Contacts and locations

Locations

  • Centro Integral Oncológico Clara Campal

    Madrid, Madrid, 28050, Spain

  • Clínica Universidad de Navarra

    Madrid, Madrid, 28027, Spain

  • Complejo Hospitalario Universitario de Pontevedra

    Pontevedra, Galicia, 36071, Spain

  • Hospital Clínic i Provincial

    Barcelona, Catalonia, 08036, Spain

  • Hospital Clínico San Carlos

    Madrid, Madrid, 28040, Spain

  • Hospital Clínico Universitario Lozano Blesa

    Zaragoza, Aragon, 50009, Spain

  • Hospital General San Jorge

    Huesca, Aragon, 22004, Spain

  • Hospital Público Lluis Alcanyis

    Xàtiva, Valencia, 46800, Spain

  • Hospital Torrecárdenas

    Almería, Andalusia, 04009, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Valencia, 46026, Spain

  • Hospital Universitario 12 Octubre

    Madrid, Madrid, 28041, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Madrid, 28040, Spain

  • Hospital Universitario Infanta Sofía

    San Sebastián de los Reyes, Madrid, 28702, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, Aragon, 50009, Spain

  • Hospital Universitario Nuestra Señora de Valme

    Seville, Andalusia, 41014, Spain

  • Hospital Universitario Son Espases

    Palma de Mallorca, Balearic Islands, 07120, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, Andalusia, 29010, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Andalusia, 41013, Spain

  • Hospital Universitario de Araba Txagorritxu

    Vitoria-Gasteiz, Basque Country, 01009, Spain

  • Hospital Universitario de Fuenlabrada

    Fuenlabrada, Madrid, 28942, Spain

  • Hospital del Mar

    Barcelona, Catalonia, 08003, Spain

  • Instituto Valenciano De Oncologia

    Valencia, Valencia, 46009, Spain

  • MD Anderson Cancer Center

    Madrid, Madrid, 28033, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.